1. Akbulut H, Icli F, Yalcin B, Demirkazik A, Onur H, Buyukcelik A, Utkan G (2004) Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma. Exp Oncol 26: 149–152
2. Bitossi R, Sculli CM, Tampellini M, Alabiso I, Brizzi MP, Ferrero A, Ottone A, Bellini E, Gorzegno G, Berruti A, Dogliotti L (2008) Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients. Anticancer Res 28: 3055–3060
3. Cercek A, Saltz L (2010) Evolving treatment of advanced colorectal cancer. Curr Oncol Rep 12: 153–159
4. Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B (2003) Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci USA 100: 8817–8822
5. Eisen T, Joensuu H, Nathan P, Harper P, Wojtukiewicz M, Nicholson S, Bahl B, Tomczak P, Wagner A, Quinn D (2011) Phase II trial of the oral multikinase inhibitor regorafenib (BAY 73-4506) as first-line therapy in patients with metastatic or unresectable renal cell cancer (RCC). Eur J Cancer 47 (Suppl): Abstract 7. 141